Drugs / Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant
Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02979535 | Nov 2016 → Mar 2019 | Dengue hemorrhagic fever, human papilloma virus infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02979535 ↗ |
| Modality | Vaccine | “a bivalent HPV (types 16 and 18) vaccine” PMID 33992441 ↗ May 2021 |
| Route | Intramuscular | “0.5 mL, IM at Day 0 and Month 6” NCT02979535 ↗ |